Benjamin Suttle

1.0k total citations · 1 hit paper
21 papers, 750 citations indexed

About

Benjamin Suttle is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Benjamin Suttle has authored 21 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Benjamin Suttle's work include Colorectal Cancer Treatments and Studies (5 papers), Renal cell carcinoma treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). Benjamin Suttle is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Renal cell carcinoma treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). Benjamin Suttle collaborates with scholars based in United States, France and United Kingdom. Benjamin Suttle's co-authors include Peter Ho, Vincent Ribrag, Jean‐Marie Michot, Takashi Owa, Carlo Lucchesi, Jean‐Charles Soria, Antoîne Italiano, Robert A. Copeland, Alicia Clawson and Heike Keilhack and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Benjamin Suttle

20 papers receiving 741 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Suttle United States	9	513	252	179	174	126	21	750
Brianne Kaiser United States	4	405 0.8×	227 0.9×	132 0.7×	104 0.6×	97 0.8×	4	607
Lawrence Garbo United States	15	311 0.6×	427 1.7×	188 1.1×	85 0.5×	84 0.7×	35	741
Sharon Friedlander United States	10	437 0.9×	333 1.3×	124 0.7×	67 0.4×	116 0.9×	35	748
M.S. Gordon United States	14	309 0.6×	212 0.8×	219 1.2×	80 0.5×	109 0.9×	89	686
Tahir Latif United States	13	211 0.4×	214 0.8×	108 0.6×	93 0.5×	70 0.6×	38	588
Christoph Heining Germany	9	240 0.5×	246 1.0×	127 0.7×	103 0.6×	118 0.9×	29	567
H. J. Illiger Germany	11	386 0.8×	555 2.2×	266 1.5×	91 0.5×	154 1.2×	28	974
Deborah Ricci United States	15	261 0.5×	474 1.9×	399 2.2×	115 0.7×	262 2.1×	51	876
Mark Woodruff United States	4	346 0.7×	117 0.5×	78 0.4×	115 0.7×	64 0.5×	10	543
IE Smith United Kingdom	6	228 0.4×	257 1.0×	121 0.7×	88 0.5×	230 1.8×	9	577

Countries citing papers authored by Benjamin Suttle

Since Specialization

Citations

This map shows the geographic impact of Benjamin Suttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Suttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Suttle more than expected).

Fields of papers citing papers by Benjamin Suttle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Suttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Suttle. The network helps show where Benjamin Suttle may publish in the future.

Co-authorship network of co-authors of Benjamin Suttle

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Suttle. A scholar is included among the top collaborators of Benjamin Suttle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Suttle. Benjamin Suttle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Aaron R., Charlene Mantia, Andrew Weickhardt, et al.. (2024). 72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations. European Journal of Cancer. 211. 114599–114599.

Sarkozy, Clémentine, Franck Morschhauser, Sydney Dubois, et al.. (2020). A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clinical Cancer Research. 26(13). 3145–3153. 54 indexed citations

Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659. 451 indexed citations breakdown →

Sarkozy, Clémentine, Franck Morschhauser, Jean‐Marie Michot, et al.. (2018). Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study. Blood. 132(Supplement 1). 4191–4191. 2 indexed citations

Smith, Sherri, Benjamin Suttle, Vincent Ribrag, et al.. (2016). Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors. Cancer Research. 76(14_Supplement). CT029–CT029. 2 indexed citations

Kieran, Mark W., Darren Hargrave, Kenneth J. Cohen, et al.. (2015). Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. Journal of Clinical Oncology. 33(15_suppl). 10004–10004. 19 indexed citations

Suttle, Benjamin, Kenneth F. Grossmann, Danièle Ouellet, et al.. (2014). A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D). Clinical Pharmacology & Therapeutics. 95. 3 indexed citations

Bendell, Johanna C., Chloé E. Atreya, Thierry André, et al.. (2014). Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).. Journal of Clinical Oncology. 32(15_suppl). 3515–3515. 45 indexed citations

Arkenau, Hendrik‐Tobias, Joaquı́n Mateo, Charlotte Lemech, et al.. (2014). A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. Journal of Clinical Oncology. 32(15_suppl). 2514–2514. 22 indexed citations

10.

McDermott, David F., Jeffrey R. Infante, Martin H. Voss, et al.. (2014). A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.. Journal of Clinical Oncology. 32(15_suppl). TPS4604–TPS4604. 5 indexed citations

11.

Blackman, Samuel C., Shelby D. Gainer, Benjamin Suttle, et al.. (2012). Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency. Cancer Research. 72(8_Supplement). 1752–1752. 6 indexed citations

12.

Lin, Ying‐Chun, Howard Ball, Benjamin Suttle, et al.. (2011). Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma.. Journal of Clinical Oncology. 29(7_suppl). 345–345. 16 indexed citations

13.

Ball, Howard, Xue Zhang, Benjamin Suttle, et al.. (2011). Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC).. Journal of Clinical Oncology. 29(15_suppl). 3061–3061. 6 indexed citations

14.

Suttle, Benjamin, Howard Ball, Mathiéu Molimard, et al.. (2010). Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 28(15_suppl). 3048–3048. 22 indexed citations

15.

McLaughlin, Megan, Andrew I. Bayliffe, Thomas L. Hunt, et al.. (2009). A Multi-Targeted Receptor Tyrosine Kinase Inhibitor for the Treatment of Neovascular AMD: Results of a Healthy Volunteer Safety and Tolerability Study of Pazopanib Eye Drops. 50(13). 5008–5008. 1 indexed citations

16.

Jones, Suzanne F., Afshin Dowlati, Benjamin Suttle, et al.. (2008). Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). Journal of Clinical Oncology. 26(15_suppl). 3552–3552. 7 indexed citations

17.

Suttle, Benjamin, Afshin Dowlati, Antoinette R. Tan, et al.. (2007). Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034). Journal of Clinical Oncology. 25(18_suppl). 14118–14118. 6 indexed citations

18.

Hurwitz, Herbert I., Afshin Dowlati, S. Savage, et al.. (2005). Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3012–3012. 64 indexed citations

19.

O’Donnell, Anne, et al.. (2003). A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). Cancer Chemotherapy and Pharmacology. 51(1). 58–66. 1 indexed citations

20.

Suttle, Benjamin & Kim L. R. Brouwer. (1995). Regional gastrointestinal absorption of ranitidine in the rat.. Pharmaceutical Research. 12(9). 1311–1315. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact